Molecular characterization of the EpCAM+ tdEVs of patients undergoing HER2-targeted therapies at follow-up time points can contribute to better comprehend the underlying mechanism of tumor resistance to anti-HER2 treatment [38], which is observed in more than 70% of HER+ breast cancer patients within a year from the initiation of the treatment [39]. This evidence concerns the gene ERBB2 and breast cancer.